期刊文献+

地西他滨联合造血干细胞移植治疗骨髓增生异常综合征转化急性白血病 被引量:3

Decitabine application combined with allogeneic hematopoietic stem cell transplantation for treatment of acute leukemia progressed from myelodysplastic syndrome
下载PDF
导出
摘要 背景:由骨髓增生异常综合征转化的急性白血病为难治白血病,临床疗效差,缓解率低,生存期短,因此探索新的有效治疗方法极为重要。目的:观察地西他滨联合造血干细胞移植治疗骨髓增生异常综合征转化急性白血病的临床疗效及并发症。方法:骨髓增生异常综合征转化的急性髓细胞白血病患者1例,先后予2个疗程地西他滨及异基因造血干细胞移植,观察临床疗效、地西他滨的毒副作用及移植相关并发症。结果与结论:经2个疗程地西他滨治疗后,达到完全缓解,主要不良反应为骨髓抑制并发感染,该患者再接受异基因造血干细胞移植后获得无病生存213d,移植过程中出现急性移植物抗宿主病及肺部感染。结果提示地西他滨联合造血干细胞移植治疗骨髓增生异常综合征转化急性白血病获得良好效果,毒副作用及相关并发症可控制,为临床上骨髓增生异常综合征转化急性白血病的治疗提供了新方法。 BACKGROUND: Acute leukemia progressed from myelodysplastic syndrome is a refractory disease with poor clinical therapeutic effect, low remission rate and short survival period. Therefore, it is extremely important to explore a new and effective treatment method. OBJECTIVE: To investigate the clinical therapeutic effects and complications of decitabine application combined with allogeneic hematopoietic stem cell transplantation in treatment of acute leukemia progressed from myelodysplastic syndrome. METHODS: One patient with acute leukemia progressed from myelodysplastic syndrome received two courses of decitabine application combined with allogeneic hematopoietic stem cell transplantation. Clinical curative effects, the side effects of decitabine and the complications of allogeneic hematopoietic stem cell transplantation were investigated. RESULTS AND CONCLUSION: The patient achieved complete remission after two courses of decitabine application combined with allogeneic hematopoietic stem cell transplantation with infection and myelosuppresison. The patient lived without disease for 213 days although acute graft-versus-host disease and pulmonary infection occurred after decitabine application combined with allogeneic hematopoietic stem cell transplantation. These findings suggest that decitabine application combined with allogeneic hematopoietic stem cell transplantation is an effective method to treat acute leukemia progressed from myelodysplastic syndrome, and the side effects and complications can be well controlled.
出处 《中国组织工程研究》 CAS CSCD 2012年第49期9253-9256,共4页 Chinese Journal of Tissue Engineering Research
  • 相关文献

参考文献9

  • 1Wijermans PW,Lübbert M,Verhoef G. An epigenetic approach to the treatment of advanced MDS,the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients[J].Annals of Hematology,2005,(Suppl 1):9-17.
  • 2Daskalakis M,Nguyen TT,Nguyen C. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment[J].Blood,2002,(08):2957-2964.
  • 3Epling-Burnette PK,List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome[J].Current Opinion in Hematology,2009,(02):70-76.
  • 4Meletis J,Viniou N,Terpos E. Novel agents for the management of myelodysplastic syndromes[J].Medical Science Monitor,2006,(09):RA194-RA206.
  • 5Dhodapkar M,Gril J,Lust JA. Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes[J].Leukemia Research,1995,(10):719-726.
  • 6Nimer SD. Myelodysplastic syndromes[J].Blood,2008,(10):4841-4851.
  • 7Kantarjian H,Issa JP,Rosenfeld CS. Decitabine improves patient outcomes in myelodysplastic syndromes:results of a phase III randomized study[J].Cancer,2006,(08):1794-1803.
  • 8张茜,白海,王存邦,王小靖,葸瑞.HLA相合同胞异基因造血干细胞移植治疗儿童MDS转变的AML 1例[J].临床血液学杂志,2008,21(2):165-166. 被引量:3
  • 9方木水,龙生平,黎龙,方莉莉,曾俊权,盛忠兰.地西他滨治疗骨髓增生异常综合征转急性白血病1例并文献复习[J].井冈山大学学报(自然科学版),2010,31(3):102-103. 被引量:5

二级参考文献12

  • 1Robertson K D,Wolffe A.DNA methylation in health and disease[J].Nat Rev Genet,2000,1:11-19.
  • 2Jones P A,Baylin SB.The epigenomics of cancer[J].Cell,2007,128:683-982.
  • 3Jones P A,Taylor SM.Cellular differentiation,cytidine anaogs and DNA methylation[J].Cell,1980,20:85-93.
  • 4Lakshmikuttyamma A,S A Scott,DeCoteau J F,et al.Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition[J].Oncogene,2010,29:576-588.
  • 5Issa J P,Garcia-Manero G,Giles F J,et al.Phase 1 study of lowdoseprolonged xposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (dexycytidine) in hematopoietic malignancies[J].Blood,2004,103:1635-1640.
  • 6Soriano A,Champlin R,McCormick G,et al.Maintenance therapy with 5-asacitidine after allogeneic stem cell transplantation for acute myelogenous leukemia and high risk myelodysplastic syndrome:a dose and schedule finding study[J].Blood,2006,108:1048a.
  • 7Kantsrjian H,Oki Y,Garcia-Manero G,et al.Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109:52-57.
  • 8RUNDE V,DE WITTE T,VAN BIEZEN A,et al. Allogeneic Stem Cell Transplantation (SCT) from HLA -identical siblings in patients with myelodysplastia and secondary acute myeloid leukem ia [J]. Bone Marrow Transpant,1999,23 (suppll) :s153--s153.
  • 9THOMAS E D. Marrow transplantation for acute nonlymphoblastic leukemia in first remission [J]. N Engl J Med,1999,301:579--581.
  • 10王晶超,李梅君.地西他滨治疗骨髓增生异常综合征的研究进展[J].中华实用诊断与治疗杂志,2008,22(8):607-609. 被引量:7

共引文献6

同被引文献13

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部